{
  "docId": "019de073-b144-743c-94c4-bc5a80eb44df",
  "docSlug": "9540d42c57dd536e8cb82c97bd211004",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 50 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 9,
  "pageCount": 50,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "Includes regulatory status and financial terms of the licensing deal.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-b144-743c-94c4-bc5a80eb44df/9",
  "deckHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df",
  "deckJsonHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df.json",
  "deckAnchorHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.09,
        "w": 0.58,
        "x": 0.05,
        "y": 0.32
      },
      "kind": "callout",
      "text": "NDA approved December 7, 2021. QIDP, Fast Track and Priority Review Designations",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b074811-c958-48a0-b618-be55f1dfc281",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.45,
        "x": 0.07,
        "y": 0.83
      },
      "kind": "disclaimer",
      "text": "*See Full Prescribing Information for the safe and effective use of XACIATO. *See important safety information on slides 20 and 21.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "409328b3-0f18-4f1b-82ad-94e55d2fe8e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.11,
        "x": 0.71,
        "y": 0.37
      },
      "kind": "image",
      "text": "ORGANON",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7b3404e-e216-4f86-9a56-0fd9f61bf6fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.69,
        "y": 0.48
      },
      "kind": "list",
      "text": "The license became effective June 2022. Daré received a $10 million upfront payment from Organon in 3Q 2022. Daré is eligible to receive potential milestone payments of up to $182.5 million and tiered double-digit royalties based on net sales.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90ba83c5-7e72-49a7-9045-ab6c4a6a4b26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.58,
        "x": 0.06,
        "y": 0.47
      },
      "kind": "list",
      "text": "XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older.* This marks the first FDA-approved product in Daré’s portfolio of potential first-in-category development candidates. XACIATO is expected to be available commercially in the U.S. in 4Q 2022.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5f5b617-1216-44fc-ab22-c0de4b2c9f30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.21,
        "x": 0.71,
        "y": 0.31
      },
      "kind": "paragraph",
      "text": "Commercialization Collaborator",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31341f5d-25fd-4da3-b4dc-2c7fe3323490",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.42,
        "x": 0.07,
        "y": 0.26
      },
      "kind": "paragraph",
      "text": "XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67e6193a-a73e-404c-bf7a-69b6f4a144a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.32,
        "x": 0.34,
        "y": 0.03
      },
      "kind": "title",
      "text": "FDA Approved – XACIATO",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ef674d3-33b0-4c70-a0a0-4d4e2b44dfb1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}